Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SA Transcripts 162.2K Followers Follow Royalty Pharma plc ( RPRX ) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 2:35 PM EDT Company Participants Pablo Legorreta - Founder, Chairman of the Board & CEO Marshall Urist - Head of Research & Investments Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Morgan Stanley, Research Division Okay. Great. Thanks for joining us, everybody. I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. I'm very pleased to be hosting this afternoon, Royalty Pharma. From -- presenting from the company, we have Pablo Legorreta, the company's CEO and Chairman. Thank you. And we have Marshall Urist, who is Head of Research and Investments. Thank you both so much for being here today to join us on the first day of our conference. Really looking forward to it. I thought maybe we'd start high level, Pablo. And then again, we'll go to some of the pipeline portfolio questions later on for Marshall. But again, as I look back, your 5-year deployment target that you set was $10 billion to $12 billion back in 2022 at your Investor Day, you hit that about a year ahead of schedule now. So how are you thinking about the next set of targets here and the deployment goal as you think about the business? Question-and-Answer Session Pablo Legorreta Founder, Chairman of the Board & CEO Well first of all, thank you for the invitation to participate in your conference and for the relationship with you and Morgan Stanley, which has been key to our growth over decades. And so yes, we have been able to invest the amount we guided when we went public, $10 billion to $12 billion